Abbott Laboratories (ABT): Diamond Hill Capital Management, LLC (Investment Advisor) added to its stake +209K shares
Diamond Hill Capital Management, LLC (Investment Advisor) added to its stake in Abbott Laboratories, per its Q1 2026 13F.
- 5.38M
- Shares reported · +209K vs prior quarter
- 3.5%
- Disclosed portfolio weight
- $552M
- Reported value
- Holdings as of
- Mar 31, 2026
- Filed
- May 7, 2026
The story around this disclosure
Every dated public record OQRO holds about the company from 60 days before to 120 days after, oldest first. It shows what was going on; none of it is a stated reason for the trade.
- Feb 10, 2026CongressDisclosed partial sale of ABT — reported range $1,001 - $15,000
- Mar 9, 2026Company filing · Form 8-K · Material agreement, New debtSigned an important agreement, and took on new debt or obligations
- Mar 13, 2026FDAFDA device clearance: Amplatzer Trevisio Intravascular Delivery System; 9-ATV06F45/609-ATV07F45/609-ATV07F45/809-ATV08F45/609-ATV08F45/809-ATV09F45/809-ATV10F45/809-ATV12F45/80
- Mar 19, 2026CongressDisclosed purchase of ABT — reported range $1,001 - $15,000
- Mar 26, 20265% stakeThe Vanguard Group reported a passive stake (13G)
- Mar 27, 2026CongressDisclosed sale of ABT — reported range $15,001 - $50,000
- Apr 16, 2026Company filing · Form 8-K · ResultsReported its results
- Apr 16, 2026FDAFDA device clearance: Disposable Radiofrequency Cannula
- Apr 16, 2026CongressDisclosed sale of ABT — reported range $15,001 - $50,000
- Apr 20, 2026FDAFDA device clearance: EnSite X EP System
- Apr 23, 2026Insider · 1 day before an 8-KCFO purchased ~$201K of ABT shares in the open market
- Apr 24, 2026Company filing · Form 8-K · Executive change, Bylaws or charterChanged a top executive or board member, and changed its bylaws, charter or fiscal year (and 1 more item)“On April 24, 2026, Kevin Conroy was named to the Abbott Laboratories’ (“Abbott”) Board of Directors. On April 24, 2026, Abbott shareholders approved the adoption of the Abbott Laboratories 2026 Incentive Stock Program (the “2026 Program”) at the Annual Meeting of Shareholders.”
- Apr 24, 2026FDAFDA device clearance: OPTIS Mobile Next Imaging System (1014932); OPTIS Integrated Next Imaging System (1014933); Ultreon 3.0 Software Upgrade Kit (ULTR300001)
- Apr 24, 2026FDAFDA device clearance: Amplatzer TorqVue Delivery System
- Apr 27, 2026Insider · Their largest buy since 2018Director purchased ~$927K of ABT shares in the open market
- Apr 28, 2026FDAFDA device clearance: Anti-HCV Next
- Apr 29, 20265% stakeVanguard Capital Management reported a passive stake (13G) of 7.5%
- May 7, 2026Insider · Their largest buy since 2019Director purchased ~$174K of ABT shares in the open market
What came next
- May 12, 2026FDARecall: Merlin" Patient Care System (PCS) software Merlin" PCS 3650 programmer Model 3330 software
- May 12, 2026CongressDisclosed sale of ABT — reported range $1,001 - $15,000
- May 15, 2026CongressDisclosed sale of ABT — reported range $1,001 - $15,000
- May 27, 2026Government · Federal Register noticeDrugs for Human Use; Drug Efficacy Study Implementation: Estrogen-Androgen Fixed-Combination Drug Products; Syntest D.S. and Syntest H.S. Tablets; Withdrawal of Hearing Requests; Final Resolution of Drug Efficacy Study Implementation 7661
- May 27, 2026CongressDisclosed partial sale of ABT — reported range $1,001 - $15,000
- Jun 12, 2026Congress · 1 personMembers of Congress: 2 purchases
- Jun 16, 2026CongressDisclosed purchase of ABT — reported range $1,001 - $15,000
- Jun 17, 2026FDAFDA device clearance: Amplatzer TorqVue Exchange System
- Jul 2, 2026FDAFDA device clearance: Amplatzer TorqVue LP Delivery System; Amplatzer TorqVue LP Catheter
- Jul 7, 2026Government · Federal Register proposed ruleMedicare Program: Hospital Outpatient Prospective Payment and Ambulatory Surgical Center Payment Systems; and Quality Reporting Programs; Including the Hospital Outpatient Quality Reporting Program and Ambulatory Surgical Center Quality Program; Request for Information on Strengthening the Standardization and Comparability of Hospital Price Transparency (HPT) Data; Prior Authorization; Accrediting Organization (AO) Deeming for Emergency Medical Treatment and Labor Act (EMTALA); and Notices of Closure of Teaching Hospitals and Opportunities To Apply for Available Slots
- Jul 8, 2026CongressDisclosed sale of ABT — reported range $1,001 - $15,000
- Jul 14, 2026CongressDisclosed sale of ABT — reported range $15,001 - $50,000
- Jul 15, 2026FDAFDA device clearance: EnSite X EP System
- Jul 16, 2026Company filing · Form 8-K · ResultsReported its results
- Jul 17, 2026CongressDisclosed sale of ABT — reported range $1,001 - $15,000
- Jul 30, 2026CongressDisclosed sale of ABT — reported range $1,001 - $15,000
- Aug 6, 2026Government · Federal Register noticeForeign-Trade Zone (FTZ) 39, Notification of Proposed Production Activity; Abbott Laboratories; (Diagnostic Medical Devices); Irving, Texas
- Aug 11, 2026InsiderOfficer sold ~$643K of ABT shares in the open market
- Aug 20, 2026FDARecall: Fisher Scientific Sure-Vue Serum/Urine hCG, Model/ Part: FHC-202/23900529, FHC-202/23900528; Beckman Coulter Inc's ICON 25 hCG, Model/ Part: FHC-202/43025; Hen…
- Aug 20, 2026FDARecall: Fisher Scientific Sure-Vue Urine hCG, Model/ Part: FHC-102/23900526; Henry Schein, Inc. One Step + Urine Cassette Test, Model/ Part: FHC-102/9004074, FHC-102/9…
How to read SEC Form 13F-HR
Form 13F is the quarterly report in which investment managers that oversee $100 million or more list the US-listed stocks and some other securities they held on the last day of the quarter.
Full guide: What is an SEC Form 13F?
What else is on file for Abbott Laboratories
For Abbott Laboratories, OQRO holds 6 insider filings (SEC Form 4 or Form 144), 3 Congress trade reports and 3 fund holdings reports (13F) dated in the last 90 days.
These are records OQRO holds, counted by their date, not a measure of how much trading took place. Routine paperwork such as option exercises and tax withholding is left out. Everything for the company is on its ABT page.
How this filing works
Explore the data
Common questions
What does this filing report about Abbott Laboratories (ABT) stock?
Diamond Hill Capital Management, LLC (Investment Advisor) added to its stake in Abbott Laboratories, per its Q1 2026 13F. Now 5.38M shares, $552M reported value, 3.5% of disclosed portfolio.
When did it happen, and when was it made public?
Holdings as of: Mar 31, 2026. Filed: May 7, 2026.
Is this a trade made on a known date?
No. A holdings report is a picture of the portfolio on the last day of the quarter. It shows what was held on that day, not the day or the price at which anything was bought or sold.
Where does this information come from?
From the SEC Form 13F-HR, a public record. The link to the official record is on this page, and OQRO copies its figures without changing them.
What else has been disclosed about Abbott Laboratories recently?
For Abbott Laboratories, OQRO holds 6 insider filings (SEC Form 4 or Form 144), 3 Congress trade reports and 3 fund holdings reports (13F) dated in the last 90 days. They are listed on the ABT page.
Does this mean ABT stock is a buy or a sell?
No. This page describes one public filing. A filing does not say why someone traded and is not a forecast, so OQRO gives no recommendation.
Is OQRO free?
Yes. Every page of OQRO is free with an account, which takes a minute with Google and needs no card. Only the AI assistant is paid.
Other disclosures at Abbott Laboratories
- SEC Form 13F-HRNov 16, 2026
- SEC Form 4Nov 6, 2026
- SEC Form 144Nov 5, 2026
- House Clerk periodic transaction reportOct 30, 2026
- House Clerk periodic transaction reportOct 27, 2026
- House Clerk periodic transaction reportOct 12, 2026
Everything OQRO holds on this company is on its ABT page.
This is one filing. OQRO holds the rest
Insider trades filed with the SEC, stock trades disclosed by members of Congress, fund holdings from 13F filings and federal contract awards, each one in plain words next to its official filing. On this page it opens why the trade stands out, what the company did around that time, the price since, and every field of the form.
OQRO is free for everyone. No card, no trial
OQRO describes public disclosures and context calculated from them. It does not give personalized advice and does not recommend any transaction. How OQRO treats data
